Hydroxysafflor yellow A

Research use only, not for human use.

Hydroxysafflor yellow A inhibited adipogenesis by increasing HSL promoter activities.

Hydroxysafflor yellow A inhibited adipogenesis by increasing HSL promoter activities. Hydroxysafflor yellow A can effectively protect the liver from long-term alcohol injury by enhancing antioxidant capacity and inhibiting the expression of TGF-β. It prevents steroid-induced avascular necrosis of femoral head by inhibiting primary bone marrow-derived mesenchymal stromal cells. Also, Hydroxysafflor yellow A has anti-tumor effects.

Cell Migration Assay Cell Line:VSMCs Concentration:0.1, 1, 10,100 μM Incubation Time:24 h Result: Inhibited LPS-induced VSMCs proliferation and migration with the concentration of 10 μM.Western Blot Analysis Cell Line:VSMCs Concentration:10 μM Incubation Time:24 h Result:Inhibited LPS-induced upregulation of pro-inflammatory factors (TNF-α, IL-6, and IL-8).Inhibited LPS-induced upregulation of TLR-4 and activation of Rac1/Akt pathway.Cell Viability Assay Cell Line:3T3-L1 Concentration:0.01, 0.1, 1, 10 mg/L Incubation Time:4, 8, 24, 48, 72, 96 h Result:Inhibit the cell viability in a dose and time-dependent manner.Apoptosis Analysis Cell Line:HepG2, Huh7 Concentration:20, 40, 80, 160 μM Incubation Time:24 hResult:Suppressed the growth and induced apoptotic cell death in both concentration and time-dependent manners.

Animal Model:Liver injury model induced by alcoholDosage:2.5 or 10 mg/kg Administration: i.p. daily for 6 weeks Result:Decreased the level of ALT and AST. Decreased the levels of HA, LN, and III-C.Increased the activities of SOD and GPx and decreased the level of TGF-β1 expression.Animal Model:Chronic obstructive pulmonary disease (COPD)Dosage:30, 48, 76.8 mg/kg Administration:i.p.Result:Inhibited the elevated IL-6, IL-1β, TNF-α, ICAM-1 and VCAM-1 mRNA Levels.Inhibited the increased phosphorylation and NF-κB p65 levels.

Hydroxysafflor yellow A | Safflomin A

TGF-beta/Smad

TGFBR

TGFβ

Cancer

——

78281-02-4

612.53338

C27H32O16

>98% (HPLC)

Pyridine, Methanol, Ethanol

O=C1C([C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)=C(O)C(O)([C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)C(O)=C1C(/C=C/C4=CC=C(O)C=C4)=O

3,4,5-trihydroxy-2-((E)-3-(4-hydroxyphenyl)acryloyl)-4-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexa-2,5-dien-1-one

(-20℃)

With Ice Pack

≥ 2 years